Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria by Wybo, Ingrid et al.
Journal of Antimicrobial Chemotherapy (2007) 59, 132–139
doi:10.1093/jac/dkl458
Advance Access publication 9 November 2006
Third Belgian multicentre survey of antibiotic susceptibility
of anaerobic bacteria
Ingrid Wybo1*, Denis Pie´rard1, Inge Verschraegen1, Marijke Reynders1,2, Kristof Vandoorslaer1,
Geert Claeys3, Michel Delme´e4, Youri Glupczynski5, Bart Gordts6, Margaretha Ieven7,
Pierrette Melin8, Marc Struelens9, Jan Verhaegen10 and Sabine Lauwers1
1Academisch Ziekenhuis Vrije Universiteit Brussel, 1090 Brussels, Belgium; 2Universitair Medisch
Centrum Sint-Pieter, 1000 Brussels, Belgium; 3Universitair Ziekenhuis Gent, 9000 Ghent, Belgium;
4Cliniques Universitaires Saint-Luc, 1200 Brussels, Belgium; 5Cliniques Universitaires de Mont-Godinne,
5530 Yvoir, Belgium; 6Algemeen Ziekenhuis Sint-Jan, 8000 Bruges, Belgium; 7Universitair Ziekenhuis
Antwerpen, 2650 Edegem, Belgium; 8Cliniques Universitaires de Lie`ge, 4000 Lie`ge, Belgium;
9Hoˆpital Universitaire Erasme, 1070 Brussels, Belgium; 10Universitair Ziekenhuis Leuven,
3000 Leuven, Belgium
Received 4 July 2006; returned 7 August 2006; revised 11 September 2006; accepted 14 October 2006
Objectives: To collect recent data on the susceptibility of anaerobes and to compare them with results
from previous studies.
Methods: Four hundred and forty-three anaerobic clinical isolates from various body sites were
prospectively collected from October 2003 to February 2005 in nine Belgian hospitals. MICs were
determined for nine anti-anaerobic and three recently developed antibiotics.
Results: Most Gram-negative bacilli except Fusobacterium spp. were resistant to penicillin. Piperacillin/
tazobactam, metronidazole, chloramphenicol, meropenem and amoxicillin/clavulanic acid were very
active against all groups, but only 86% of Bacteroides fragilis group strains were susceptible to the
latter. Cefoxitin, cefotetan and clindamycin were less active. In particular, only 62%, 52% and 48% of
B. fragilis group strains were susceptible, respectively. Clindamycin shows a continuing decrease in
activity, as 83% were still susceptible in 1987 and 66% in 1993–94. Anti-anaerobic activity of the new
antibiotics is interesting, with MIC50 and MIC90 of 1 and >32 mg/L for moxifloxacin, 2 and 4 mg/L for
linezolid and 0.5 and 8 mg/L for tigecycline.
Conclusions: The susceptibility of anaerobic bacteria remains stable in Belgium, except for clindamycin,
which shows a continuous decrease in activity. However, for each of the tested antibiotics, at least a few
resistant organisms were detected. Consequently, for severe infections involving anaerobic bacteria, it
could be advisable to perform microbiological testing instead of relying on known susceptibility profiles.
Periodically monitoring background susceptibility remains necessary to guide empirical therapy.
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Introduction
Anaerobic bacteria are commonly found in polymicrobial
infections. Antimicrobial therapy for the management of infec-
tions with a high probability of anaerobic aetiology includes an
antimicrobial agent with known efficacy against anaerobes.
Antibiotic resistance among anaerobic bacteria has increased in
recent years and it has been reported against antibiotics that were
previously thought to be universally active, such as carbapenems
and imidazoles.1 Since anaerobic cultures are cumbersome and
susceptibility testing of anaerobic isolates is generally not
performed routinely, it is important to have good knowledge of
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background susceptibility to avoid the use of inappropriate
empirical antibiotics. Therefore, it is recommended to periodi-
cally monitor local and regional resistance patterns.2 Two
multicentre surveys have already been performed in Belgium,
the first one in 19873 and the second one in 1993–94.4 Since that
time no published data are available about antimicrobial
susceptibility of anaerobic bacteria. The objective of this study
was to collect recent data on the susceptibility of anaerobes in our
country. The results were analysed in reference to the previous
surveys.
Materials and methods
Bacteria
Strains were collected from October 2003 to February 2005 in 8
Belgian university hospitals and one general hospital: Academisch
Ziekenhuis Vrije Universiteit Brussel (Brussels), Hoˆpital Universitaire
Erasme (Brussels), Cliniques Universitaires Saint-Luc (Brussels),
Universitair Ziekenhuis Antwerpen (Antwerp), Universitair Zieken-
huis Leuven (Leuven), Centre Hospitalier Universitaire du Sart-Tilman
(Lie`ge), Cliniques Universitaires de Mont-Godinne (Yvoir), Algemeen
Ziekenhuis Sint-Jan (Brugge) and Universitair Ziekenhuis Gent
(Ghent). Six of these centres participated in the previous surveys.
Each centre collected prospectively up to 50 unselected, non-
duplicated clinically significant strict anaerobic isolates. Specimen
source was recorded for each isolate. The isolates were sent for
susceptibility testing to the microbiology laboratory of the Academisch
Ziekenhuis Vrije Universiteit Brussel.
Identification
Species identification was performed by standard methods in the
collecting laboratories. Identification was checked at the Academisch
Ziekenhuis Vrije Universiteit Brussel by analysis of cellular fatty acid
composition using the Microbial Identification System (MIS),
followed by appropriate biochemical or enzymatic tests5 if the MIS
results did not support the identification of the collecting laboratory.
Susceptibility testing
The antibiotic susceptibility was determined by Etest methodology
(AB Biodisk, Solna, Sweden), which was previously shown to
produce accurate results for susceptibility testing of anaerobic
bacteria.6 Brucella agar supplemented with laked sheep blood, haemin
and vitamin K1 was used as recommended for the CLSI (formerly
NCCLS) reference agar dilution procedure.2 The following anti-
microbial agents were tested: penicillin, amoxicillin/clavulanic acid,
clindamycin, metronidazole, meropenem, chloramphenicol, cefoxitin,
cefotetan, moxifloxacin, linezolid and piperacillin/tazobactam. The
agar plates were inoculated with a McFarland 1 suspension and
incubated in anaerobiosis. The results were read after 48 h. For slow
growers, reading was performed after 72 h. Interpretation was carried
out according to the manufacturer’s recommendations. Because of the
unavailability of tigecycline Etest strips when the study was
performed the MIC of this antimicrobial agent was determined by
the CLSI agar dilution procedure.2 Bacteroides fragilis ATTC 25285,
Bacteroides thetaiotaomicron ATCC 29741 and Eubacterium lentum
ATCC 43055 were included as control strains in each test run. The
isolates were categorized by using the following breakpoints for
susceptible and resistant strains, respectively: penicillin2 0.5 and
2 mg/L, amoxicillin/clavulanic acid2 4/2 and16/8, clindamycin2
2 and 8, metronidazole2 8 and 32, meropenem2 4 and 16,
chloramphenicol2 8 and 32, cefoxitin2 16 and 64, cefotetan2
16 and 64, moxifloxacin7 1 and 4, linezolid8 4 and >4,
piperacillin/tazobactam2 32/4 and 128/4 and tigecycline 2 and
8 (the latter as recommended by the manufacturer). In addition, a
b-lactamase test was performed on each isolate by using the nitrocefin
test. Since some breakpoints differ slightly from those used in the
report of the 1987 survey and in addition an intermediate category has
now been established, all 1987 data were computed again using the
individual MIC results for comparison between the surveys.
Results
Four hundred and forty-three (443) anaerobic isolates were
collected from various sources: 151 from abdominal sites, 98
from blood, 70 from wounds and pus, 46 from abscesses, 14 from
the respiratory tract, 11 from gynaecological and obstetrical sites,
6 from the central nervous system, 6 from ear and sinus, and 41
from miscellaneous other sites.
Table 1 summarizes the susceptibility results for the different
groups of anaerobes. Table 2 compares the percentages of
susceptible strains in this present survey with those found in the
1993–94 and 1987 surveys. The distribution of individual species
is presented in the footnotes of Table 1 for the strains of this study
and can be found in original reports for the previous surveys.3,4
Overall, b-lactamases were detected in 62% of the 443 isolates.
Most b-lactamase-producing strains belong to the B. fragilis
group (98% b-lactamase-positive) and to the group of Prevotella
spp. and other Gram-negative bacilli (70% b-lactamase-positive).
As compared with the previous surveys of 1987 and 1993–94, the
percentage of b-lactamase-producing strains increased in this last
group from 31% to 57% and 70%, respectively. Among
Clostridium spp. 5 b-lactamase-producing clostridia (3 Clostri-
dium clostridioforme, 1 Clostridium tertium and 1 Clostridium
spp.) out of 57 isolates (9%) were detected in this study. In 1993–
94 only one b-lactamase-positive Clostridium isolate was found.
In 1987 all clostridia were b-lactamase-negative. All other
organisms including all Fusobacterium were b-lactamase-
negative in the three surveys.
Penicillin, a compound very susceptible to b-lactamases, was
active against only 1% of B. fragilis group strains, a result similar
to that of the previous studies. The susceptibility of Prevotella
spp. and other Gram-negative bacilli decreased markedly from
64% in 1987 to 48% in 1993–94 and to only 26% in this survey.
Penicillin activity was much better against other anaerobic
isolates. However, a decrease in the prevalence of penicillin-
susceptible isolates was seen in Clostridium spp., non-spore-
forming Gram-positive bacilli and anaerobic cocci from 91%,
93% and 92% in 1987 to 83%, 81% and 84% in this survey,
respectively. In contrast, all Fusobacterium isolates in this survey
were susceptible to penicillin compared with 70% and 88% in
1987 and 1993–94, respectively.
The activity of cefoxitin was less affected by the b-lactamases:
62% of B. fragilis group strains and 98% of Prevotella spp. and
other Gram-negative bacilli were susceptible. Eighty-six percent
(86%) of B. fragilis strains were susceptible as opposed to 30% of
strains belonging to other species of the B. fragilis group. The
susceptibility rates of all other groups of anaerobes were high
(>90%).
Cefotetan was less active than cefoxitin against anaerobic
Gram-negative bacilli: 52% of B. fragilis group strains and 86%
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Table 1. Antimicrobial activities of 12 antibiotics against different groups of anaerobes
Organism Antimicrobial agent Range (mg/L) MIC50 MIC90 %S %I %R
Bacteroides fragilis groupa penicillin 0.25–>32 >32 >32 1 0 99
(238 strains) (98% cefotetan 2–>256 16 >256 52 5 43
b-lactamase-positive) cefoxitin 0.5–>256 16 128 62 18 20
amoxicillin/clavulanate 0.25–32 0.5 8 86 9 5
piperacillin/tazobactam <0.016–>256 1 32 95 3 2
meropenem 0.016–32 0.125 1 97 2 1
clindamycin <0.016–256 4 >256 48 13 39
metronidazole <0.016–32 0.5 1 99 0 1
chloramphenicol 0.5–16 4 8 99 1 0
moxifloxacin 0.125–>32 1 >32 52 16 32
linezolid 0.5–16 2 4 99 0 1
tigecycline 0.125–32 1 8 73 8 19
B. fragilis (135 strains) penicillin 0.25–>32 >32 >32 1 0 99
(98% b-lactamase-positive) cefotetan 2–>256 8 64 83 3 14
cefoxitin 2–256 8 32 86 7 7
amoxicillin/clavulanate 0.25–16 0.5 4 92 7 1
piperacillin/tazobactam <0.016–8 0.5 2 100 0 0
meropenem 0.064–32 0.125 0.5 96 2 2
clindamycin 0.032–>256 2 >256 60 10 30
metronidazole 0.064–32 0.5 1 99 0 1
chloramphenicol 1–8 4 8 100 0 0
moxifloxacin 0.125–>32 1 >32 68 5 27
linezolid 0.5–8 2 4 99 0 1
tigecycline 0.25–32 1 8 80 2 18
B. fragilis group without penicillin 0.25–>32 >32 >32 1 0 99
B. fragilis (103 strains) cefotetan 2–>256 >256 >256 11 8 81
(99% b-lactamase-positive) cefoxitin 0.5–>256 32 256 30 33 37
amoxicillin/clavulanate 0.25–32 1 16 78 11 11
piperacillin/tazobactam 0.06–>256 16 64 89 7 4
meropenem 0.016–8 0.25 1 98 2 0
clindamycin <0.016–>256 4 >256 33 17 50
metronidazole <0.016–32 0.5 1 99 0 1
chloramphenicol 0.5–16 4 8 98 2 0
moxifloxacin 0.125–>32 2 >32 30 30 40
linezolid 0.5–16 2 4 98 0 2
tigecycline 0.125–32 1 8 64 15 21
Fusobacterium penicillin <0.002–0.25 0.016 0.125 100 0 0
spp.b (30 strains) cefotetan 0.016–8 0.062 1 100 0 0
(0% b-lactamase-positive) cefoxitin <0.016–8 0.064 1 100 0 0
amoxicillin/clavulanate <0.016–4 0.032 0.5 100 0 0
piperacillin/tazobactam <0.016–8 0.016 1 100 0 0
meropenem <0.002–0.5 0.006 0.064 100 0 0
clindamycin <0.016–8 0.032 0.125 90 3 7
metronidazole <0.016–0.5 0.016 0.125 100 0 0
chloramphenicol 0.25–2 0.25 0.5 100 0 0
moxifloxacin 0.016–>32 0.5 2 80 10 10
linezolid 0.03–1 0.25 0.25 100 0 0
tigecycline 0.03–0.25 0.125 0.25 100 0 0
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Table 1. (continued)
Organism Antimicrobial agent Range (mg/L) MIC50 MIC90 %S %I %R
Prevotella species and other penicillin 0.004–>32 32 >32 26 2 72
Gram-negative bacillic cefotetan 0.03–128 4 32 86 6 8
(50 strains) (70% cefoxitin <0.016–64 1 16 98 0 2
b-lactamase-positive) amoxicillin/clavulanate <0.016–4 0.125 2 100 0 0
piperacillin/tazobactam <0.016–>256 0.125 1 98 0 2
meropenem 0.03–0.5 0.064 0.125 100 0 0
clindamycin <0.016–>256 0.032 >256 82 0 18
metronidazole <0.016–8 0.125 1 100 0 0
chloramphenicol 0.125–4 1 4 100 0 0
moxifloxacin 0.03–>32 0.5 16 70 6 24
linezolid 0.25–8 1 2 98 0 2
tigecycline 0.062–2 0.25 0.5 100 0 0
Clostridium spp.d (57 strains) penicillin 0.032–>32 0.125 2 83 5 12
(9% b-lactamase-positive) cefotetan 0.064–>256 0.125 4 95 2 3
cefoxitin 0.25–>256 1 16 91 4 5
amoxicillin/clavulanate <0.016–8 0.064 1 97 3 0
piperacillin/tazobactam 0.032–>256 0.125 8 97 0 3
meropenem 0.003–8 0.016 1 98 2 0
clindamycin 0.016–>256 1 256 63 14 23
metronidazole <0.016–16 0.5 2 98 2 0
chloramphenicol 1–32 4 8 95 3 2
moxifloxacin 0.125–>32 0.5 32 86 2 12
linezolid 0.5–16 2 4 98 0 2
tigecycline 0.064–8 0.5 4 84 14 2
Non-spore-forming penicillin <0.002–4 0.032 2 81 3 16
Gram-positive bacillie cefotetan 0.125–>256 0.5 >256 81 0 19
(31 strains) (0% cefoxitin 0.032–16 0.25 8 100 0 0
b-lactamase-positive) amoxicillin/clavulanate <0.016–2 0.064 0.5 100 0 0
piperacillin/tazobactam 0.016–32 0.125 32 100 0 0
meropenem 0.008–0.5 0.064 0.5 100 0 0
clindamycin <0.016–>256 0.064 1 90 0 10
metronidazole 0.016–>256 >256 >256 35 0 65
chloramphenicol 0.064–32 0.25 4 97 0 3
moxifloxacin 0.032–64 0.125 1 90 7 3
linezolid 0.064–8 0.25 1 97 0 3
tigecycline 0.064–0.5 0.125 0.25 100 0 0
Anaerobic coccif (37 strains) penicillin 0.002–>32 0.064 8 84 2 14
(0% b-lactamase-positive) cefotetan 0.064–2 0.5 2 100 0 0
cefoxitin <0.016–4 0.25 2 100 0 0
amoxicillin/clavulanate <0.016–4 0.064 1 100 0 0
piperacillin/tazobactam <0.016–64 0.064 32 92 8 0
meropenem <0.002–0.064 0.016 0.064 100 0 0
clindamycin <0.016–>256 0.25 4 89 6 5
metronidazole 0.016–2 0.25 1 100 0 0
chloramphenicol 0.25–256 0.5 1 97 0 3
moxifloxacin 0.032–64>32 0.25 >32 68 10 22
linezolid 0.25–2 0.5 1 100 0 0
tigecycline 0.032–1 0.125 0.5 100 0 0
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of Prevotella spp. and other Gram-negative bacilli were
susceptible. Susceptibility of B. fragilis strains to cefotetan was
83% in contrast to 11% of the other species in the B. fragilis
group.
Ninety-eight per cent (98%) of all isolates were susceptible to
meropenem. Six of 135 B. fragilis strains were intermediate
(MIC = 8 mg/L) or resistant to meropenem (MIC  16 mg/L). In
addition, one Bacteroides caccae isolate, one Bacteroides
stercoris isolate and one Clostridium glycolicum isolate were
intermediate to meropenem. In 1993–94 all isolates were
susceptible to imipenem.
Two b-lactam/b-lactamase inhibitor combinations were tested
in this study: amoxicillin/clavulanic acid and piperacillin/
tazobactam. The activity of the b-lactam antibiotic was partially
restored by the addition of a b-lactamase inhibitor. Overall
activities of amoxicillin/clavulanic acid and piperacillin/
tazobactam in this survey were 92% and 96%, respectively. In
the previous surveys susceptibility to these combinations was
>95% (piperacillin/tazobactam was not tested in 1987). Resistance
to amoxicillin/clavulanic acid is limited to the B. fragilis group,
with the exception of a few intermediate Clostridium spp. strains.
In the B. fragilis group, 92% of B. fragilis and 78% of other
B. fragilis group strains were susceptible to amoxicillin/clavulanic
acid in this survey, as compared with 95% and 89% in 1993–94
and 97% and 94% in 1987, respectively. Four hundred and twenty-
six (426) isolates were susceptible to piperacillin/tazobactam,
10 intermediate (5 B. thetaiotaomicron, 2 Bacteroides vulgatus
and 3 Veillonella parvula) and 7 resistant (1 B. stercoris, 2
B. thetaiotaomicron, 1 Bacteroides uniformis, 1 Bilophila
wadsworthia and 2 C. clostridioforme).
Chloramphenicol was very active against all anaerobic isolates
(98% overall) with susceptibility exceeding 95% in all groups.
Susceptibility to metronidazole remains stable. Overall suscept-
ibility was 95% and was high in all groups except non-spore-
forming Gram-positive bacilli: all Propionibacterium acnes (19
isolates) and one Lactobacillus sp. were resistant. Overall activity
of clindamycin decreased from 83% in 1987 to 72% in 1993–94
and to 63% in this survey. Only 33% of non-B. fragilis strains in
the B. fragilis group were susceptible to clindamycin, as
compared with 60% of B. fragilis strains.
For linezolid, moxifloxacin and tigecycline no CLSI break-
points for anaerobes are available. Overall, MIC50 and MIC90 were
2 and 4 mg/L for linezolid and 99% of isolates were susceptible to
4 mg/L linezolid. Resistance to linezolid (MIC > 4 mg/L) was
found in only six isolates, belonging to the following species:
B. fragilis (MIC = 8 mg/L), Bacteroides ovatus (MIC = 8 mg/L),
B. uniformis (MIC = 16 mg/L), B. wadsworthia (MIC = 8 mg/L),
Eubacterium species (MIC = 8 mg/L) and Clostridium subtermina
(MIC = 16 mg/L). These isolates were susceptible to amoxicillin/
clavulanic acid, meropenem and metronidazole.
For moxifloxacin, MIC50 and MIC90 were 1 and >32 mg/L.
Overall susceptibility to 1 mg/L moxifloxacin was 64%. In the
Table 1. (continued)
Organism Antimicrobial agent Range (mg/L) MIC50 MIC90 %S %I %R
All anaerobes (443 strains) penicillin <0.002–>32 >32 >32 34 1 65
(62% b-lactamase-positive) cefotetan 0.016–>256 8 >256 70 4 26
cefoxitin <0.016–>256 8 64 78 10 12
amoxicillin/clavulanate <0.016–32 0.5 4 92 5 3
piperacillin/tazobactam <0.016–>256 0.5 32 96 2 2
meropenem <0.002–32 0.125 0.5 98 1 1
clindamycin <0.016–>256 1 >256 63 10 27
metronidazole <0.016–>256 0.5 2 95 0 5
chloramphenicol 0.064–256 4 8 98 1 1
moxifloxacin 0.016–>32 1 >32 64 12 24
linezolid 0.03–16 2 4 99 0 1
tigecycline 0.03–32 0.5 8 84 6 10
aIncludes Bacteroides fragilis (135 strains), Bacteroides caccae (6 strains), Bacteroides distasonis (6 strains), Bacteroides eggerthii (1 strain), Bacteroides ovatus
(12 strains), Bacteroides stercoris (3 strains), Bacteroides thetaiotaomicron (46 strains), Bacteroides uniformis (7 strains) and Bacteroides vulgatus (22 strains).
bIncludes Fusobacterium mortiferum (1 strain), Fusobacterium necrophorum (10 strains), Fusobacterium nucleatum (16 strains), Fusobacterium varium
(3 strains).
cIncludes Bacteroides capillosus (1 strain), Bacteroides ureolyticus (1 strain), Bilophila wadsworthia (2 strain), Capnocytophaga ochracea (1 strain),
Capnocytophaga sputigena (1 strain), Porphyromonas endodontalis (1 strain), Prevotella bivia (8 strains), Prevotella buccae (5 strains), Prevotella denticola
(1 strain), Prevotella intermedia/nigrescens (3 strains), P. intermedia/nigrescens (2 strains), Prevotella melaninogenica (4 strains), P. melaninogenica group
(2 strains), Prevotella oralis (5 strains), Prevotella oris (3 strains), Prevotella species (9 strains), Prevotella tannerae (1 strain).
dIncludes Clostridium bifermentans (1 strain), Clostridium clostridioforme (3 strains), Clostridium glycolicum (2 strains), Clostridium innocuum (1 strain),
Clostridium perfringens (37 strains), Clostridium ramosum (3 strains), Clostridium septicum (2 strains), Clostridium sordelli (1 strain), Clostridium species
(2 strains), Clostridium sporogenes (1 strain), Clostridium subterminale (1 strain) and Clostridium tertium (3 strains).
eIncludes Eggerthella lenta (6 strains), Eubacterium limosum (1 strain), Eubacterium species (2 strains), Lactobacillus species (1 strain), Propionibacterium
acnes (19 strains), Solobacterium moorei (2 strains).
fIncludes Anaerococcus hydrogenalis (1 strain), Anaerococcus vaginalis (3 strains), Finegoldia magna (8 strains), Micromonas micros (9 strains),
Peptostreptococcus anaerobius (1 strains), Peptostreptococcus species (2 strains), Peptostreptococcus asaccharolyticus (1 strain), Peptoniphilus
asaccharolyticus (4 strains), Peptoniphilus ivorii (1 strain) and Veillonella parvula (7 strains).
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B. fragilis group, 68% of B. fragilis and 30% of non-B. fragilis
strains were susceptible to moxifloxacin at this breakpoint. In
other groups susceptibility was 80% for Fusobacterium spp., 70%
for Prevotella spp. and other Gram-negative bacilli, 86% for
Clostridium spp., 90% for non-spore-forming Gram-positive
bacilli and 68% for anaerobic cocci.
MIC50 and MIC90 of tigecycline were 0.5 and 8 mg/L,
respectively. At the susceptibility breakpoint of 2 mg/L, 84% of
isolates were susceptible to tigecycline; 73% in the B. fragilis
group and 84% in Clostridium spp. All other isolates were
susceptible at this breakpoint.
Discussion
Mixed polymicrobial infections involving anaerobic bacteria are
most commonly treated empirically, without any laboratory
documentation by cultures and susceptibility testing. Over the
past 20 years, however, significant antibiotic resistance has been
identified among several species of anaerobic bacteria. Many
Gram-negative anaerobes presently display unpredictable sus-
ceptibilities to antimicrobial agents, which may result in an
inappropriate choice of empirical antimicrobial therapy. Until
recently, there was no consensus about the influence of
antimicrobial resistance on the clinical outcome of infections
involving anaerobes.9,10 The often polymicrobial nature of the
infection and the contribution of surgical drainage may indeed
obscure the importance of resistant organisms. Two studies
underscore the importance of appropriate choice of therapy. A
Finnish retrospective study9 including 57 patients with clinically
significant anaerobic bacteraemia evaluated the effect of the
choice of antimicrobial therapy on the outcome for patients.
Twenty-eight patients received appropriate antimicrobial treat-
ment; for 18 patients (32%) an initially inappropriate therapy was
changed on the basis of the bacteriological results and for 11
patients the treatment remained unchanged and was not adjusted
to the laboratory results. In these three groups, the mortality rate
was 18%, 17% and 55%, respectively. Failure to adjust therapy
according to the bacteriological results thus had a serious impact
on outcome. A recent multicentre prospective observational trial10
on bacteraemia with Bacteroides spp. showed that ineffective
therapy results in adverse clinical outcomes such as higher
mortality, more clinical failure and bacteriological persistence as
compared with effective therapy. However, since anaerobic
susceptibility results often are not obtained within a useful time
frame, periodic surveys are still needed for conducting empirical
therapy.
The comparison of the results of the present survey with those
of the previous studies (1987 and 1993–94) shows some important
evolutions in the antibiotic susceptibility of anaerobic bacteria in
Belgium. The most striking evolution is the regular increase in
clindamycin resistance: non-susceptible strains increased from
17% in 1987, to 28% in 1993–94 and to 37% in 2003–2004. This
can be explained only partially by a different species distribution
(more Gram-negative bacilli in 2003–2004). The decrease in
activity against B. fragilis group strains and clostridia to 48% and
to 63%, respectively, makes clindamycin useless for empirical
treatment of severe anaerobic infections.
Overall, b-lactamase-producing strains increased from 41% in
1987 and 48% in 1993–94 to 62% in this survey. This rise can be
partly attributed to a change in the species distribution. In 1987
and 1993–94, 56% and 58% of Gram-negative bacilli, respec-
tively, were included in contrast to 71% in this survey. As
expected, a high rate of b-lactamase-producing strains was
recorded in the B. fragilis group (98%), corroborating the CLSI
recommendation to report all members of the B. fragilis group as
resistant to penicillin.2 Remarkable was the continuous increase in
b-lactamase positivity, up to 70% of the Prevotella spp. and other
Gram-negative bacilli group, and the appearance of b-lactamase-
positive Clostridium spp. strains (9%).
Overall 66% of strains were found to be not susceptible to
penicillin. This antibiotic is no longer useful in empirical
treatment of anaerobic infections. Previously it was considered
the drug of choice for anaerobic infections above the diaphragm.
However, taking into account the increasing resistance to
penicillin of Prevotella spp., often present in oropharyngeal
Table 2. Percentage of susceptible isolates for each antimicrobial agent tested during the three surveys: comparison of results from this
study with previous surveys3,4
Penicillin
Amoxicillin/
clavulanate Clindamycin Metronidazole Chloramphenicol
Organisms 1987 1993–94 2004 1987 1993–94 2004 1987 1993–94 2004 1987 1993–94 2004 1987 1993–94 2004
Bacteroides fragilis group 2 2 1 96 93 86 83 66 48 100 98 99 99 100 99
B. fragilis 0 2 1 97 95 92 90 85 60 100 100 99 99 100 100
B. fragilis group
without B. fragilis
4 3 1 94 89 78 75 37 33 100 95 99 100 100 98
Fusobacterium spp. 70 88 100 100 100 100 90 69 90 100 100 100 100 100 100
Prevotella species and other
Gram-negative bacilli
64 48 26 95 100 100 90 91 82 100 96 100 100 100 100
Clostridium spp. 91 90 83 100 100 97 82 74 63 100 100 98 96 100 95
Non-spore-forming
Gram-positive bacilli
93 77 81 100 100 100 93 82 90 36 36 35 100 100 97
Anaerobic cocci 92 81 84 98 96 100 94 89 89 94 95 100 98 100 97
Total 46 38 34 97 96 92 83 72 63 95 94 95 97 99 98
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flora, this policy must be reconsidered as well. In patients with
gas gangrene, penicillin G in high dosages is still considered to be
the drug of choice. However, animal studies have demonstrated
that protein synthesis inhibitors were better inhibitors of toxin
synthesis than were cell-wall-active agents. For this reason, it is
now recommended to combine clindamycin with penicillin in
serious clostridial infections if clindamycin is still active.11
The activity of cefoxitin in this survey, once considered as
the most active cephalosporin against anaerobes, was comparable
with the results of the previous study (1993–94) except for
the B. fragilis group. Eighty-six per cent of B. fragilis were
susceptible in both surveys. Susceptibility of other species of the
B. fragilis group, still 51% in 1993–94, was further reduced to
30%. In all other groups more than 90% of the isolates were found
to be susceptible to cefoxitin. Cefotetan was even less active than
cefoxitin against the B. fragilis group. Only 11% of non-
B. fragilis species were susceptible. Because of the high rate of
resistance of the B. fragilis group to cefoxitin and cefotetan, these
agents are not recommended for empirical treatment of serious
Bacteroides infections. Their role in prophylaxis of surgical site
infection in abdominal and pelvic surgery should also be
reconsidered seriously.
In the two b-lactam/b-lactamase inhibitor combinations tested
in this study, amoxicillin/clavulanic acid and piperacillin/
tazobactam, the activity of the b-lactam antibiotic was restored
by the addition of a b-lactamase inhibitor in most organisms. In the
previous study (1993–94) these agents showed an overall activity
in excess of 95%. Overall activity is still 96% for piperacillin/
tazobactam; in contrast it is reduced to 92% for amoxicillin/
clavulanic acid. Decrease in susceptibility is especially pro-
nounced in non-B. fragilis species of the B. fragilis group for both
combinations: 78% for amoxicillin/clavulanic acid and 89% for
piperacillin/tazobactam. Within this group, the resistance appeared
evenly distributed, except for Bacteroides distasonis: three of the
six isolates were resistant and one intermediate.
The majority of isolates were susceptible to carbapenems. All
strains were susceptible to imipenem in 1993–94. In this survey
only a few isolates of the B. fragilis group and of clostridia were
not susceptible to meropenem.
Chloramphenicol preserves an excellent activity against all
anaerobes. This antibiotic with good tissue penetration can be of
use in the treatment of cases where its benefit exceeds the risks of
toxicity. Metronidazole resistance remains exceptional.
Linezolid, the first of a new class of antimicrobial agents, the
oxazolidinones, showed promising activity against the tested
isolates. Four hundred and thirty-seven of 443 isolates were
susceptible to linezolid if 4 mg/L was used as the breakpoint.
Experience with linezolid in the treatment of anaerobic infections
is, however, still limited and clinical trials would be useful.
Activity of moxifloxacin was less favourable especially against
the B. fragilis group. At concentrations of 1, 2 and 4 mg/L
moxifloxacin inhibited only 64%, 76% and 83% of isolates,
respectively. Twelve per cent of the isolates had an MIC of
moxifloxacin >32 mg/L. When MIC distributions for B. fragilis
were examined, a bimodal distribution was observed with a first
peak at 0.5 mg/L and a smaller peak at >32 mg/L, while the
distribution presented on the website of EUCAST shows only one
peak at 0.5 mg/L (data not shown). It is possible that the wide
usage of quinolones in Belgium—ranking third in a recent
European survey on use of quinolones in ambulatory medicine—
already selected this resistant subpopulation.12
For tigecycline, a new glycylcycline derivate of minocycline, a
susceptibility breakpoint of 2 mg/L was used in clinical trials.
Subsequently FDA proposed 4 mg/L for anaerobes based on
MICs for responsive organisms. If this breakpoint is used instead
of 2 mg/L, susceptibility to tigecycline rises to 81% for the
B. fragilis group and to 98% for Clostridium spp.
In conclusion, piperacillin/tazobactam, meropenem and metro-
nidazole remain very useful antimicrobial agents for the treatment
of anaerobic infections. However, resistant organisms were
detected for each of these agents. Therefore susceptibility testing
of anaerobic isolates is indicated in severe infections to confirm
appropriateness of antimicrobial therapy. Periodically monitoring
background susceptibility is necessary to guide empirical
treatment. New antimicrobial agents with interesting anti-
anaerobic activity are available and should be evaluated in
clinical trials.
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